Sonic Healthcare (ASX:SHL) acquires US ProPath

Company News

by Lauren Evans

Medical laboratory company Sonic Healthcare (ASX:SHL) has acquired US pathology company ProPath, based in Texas.

While the price was not specified, Sonic said ProPath has around US $110 million in annual revenue and serves more than 20 hospital groups across 45 states. Sonic said the acquisition is a very significant step in the ongoing development of Sonic’s AP and clinical laboratory operations in the US. 

“ProPath has an outstanding reputation as a top-quality pathology company, with outstanding pathologists, managers and staff who have driven strong organic growth over decades based on clinical expertise and focus on physician and patient satisfaction,” said Sonic’s CEO Colin Goldschmidt.

The acquisition was funded from cash and available debt lines, and will be immediately earnings per share accretive, according to Sonic. 

Shares in Sonic Healthcare (ASX:SHL) are trading 0.8 per cent lower at $43.88. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.